High-Grade Supraclavicular Soft Tissue Sarcoma as Secondary Malignancy After Successful Treatment of Acute Myeloid Leukemia: Case Report and Literature Review

Troeltzsch, Matthias; Stimmer, Herbert; Langer, Rupert; Troeltzsch, Markus; Steiner, Timm; Wolff, Klaus‐Dietrich

doi:10.1016/j.joms.2011.10.008

Cited by 1 publication

(1 citation statement)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although there are many reports about the risk of developing secondary malignancy after chemotherapy, post-chemotherapy STS has not been outside of pediatric malignancies. [23][24][25] In our study, there were no STS-AMP cases with a past history of pediatric malignant tumors as a preceding malignancy and no cases were considered to be chemotherapy-induced STS. Furthermore, chemotherapy for APMs did not show any prognostic risk.…”

Section: Discussionmentioning

confidence: 78%

The impact of antecedent primary malignancy in soft tissue sarcoma patients

Torigoe

Imanishi

Yazawa

et al. 2019

J Orthop Surg (Hong Kong)

View full text Add to dashboard Cite

Background: It is unclear whether antecedent primary malignancies (APMs) have any negative impact on the prognosis of soft tissue sarcoma (STS). We retrospectively reviewed STS patients with APMs (STS-APM) and compared their survival to those of STS only (STS-O). Methods: Twenty-one cases of STS-APM from 2008 to 2017 in our institution were analyzed. One hundred and seventy cases of STS-O at the same period were compared as a control group. Overall survival was estimated using Kaplan-Meier survival curves and prognostic factors were analyzed using logistic regression analyses and contingency table analyses. Results: As the final status of STS-APM patients, 12 patients were in disease-free survival, 5 were alive with disease, 3 have died of disease, and 1 has died of another disease. There was no case that died of APM. The 5-year overall survival rates were 88% in STS-APM and 78% in STS-O, showing no statistical significant (p ¼ 0.65). The 5-year overall survival rates in each stage of STS-APM and STS-O were 100/100% in stage I, 100/85% in stage II, 86/72% in stage III, and the 3-year overall survival rates were 67/51% in stage IV, with no statistical significance. With regard to prognostic factor, histological grade of STS was the only significant factor. Although antecedent radiotherapy tended to show a high odds ratio, the association was not statistically significant. Antecedent chemotherapy did not show any estimated prognostic risk. Conclusions: Our study suggested that APM in STS patient would not be a negative prognostic factor.

show abstract

Section: Discussionmentioning

confidence: 78%